RXRγ、RARβ在9-cis-RA抑制人胃癌SGC7901细胞生长中的作用  

Inhibitory Effect of RXRγ and RARβ on Growth of Human Gastric Carcinoma Cell Line SGC7901 Treated by 9-cis-RA

作　　者：刘莹[1] 朱祖安[2] 崔涛[1] 刘霞[3] 

机构地区：[1]徐州医学院病理学教研室,221004 [2]徐州医学院附属医院消化内科 [3]徐州市中心医院病理科

出　　处：《天津医药》2009年第12期1000-1003,I0009,共5页Tianjin Medical Journal

基　　金：江苏省高校自然科学基金(项目编号:05KJD320234);徐州市科技局基金(项目编号:06-34)

摘　　要：目的:探讨维甲类X受体(RXR)γ、RARβ在RXR激动剂9-顺维甲酸(9-cis-RA)抑制人胃癌SGC7901细胞生长中的作用。方法:体外培养SGC7901细胞给予9-cis-RA干预,四甲基偶氮唑蓝(MTT)法、流式细胞术、HE染色、免疫组化染色、Western-blot检测9-cis-RA作用后SGC7901细胞生长情况、凋亡率、细胞周期的改变、RXRγ及RARβ表达情况。结果:SGC7901细胞与9-cis-RA共同培养48h后,肿瘤细胞生长受到抑制,其作用具有浓度及时间依赖性。流式细胞仪检测显示处于G0/G1期的细胞增多,凋亡率增高,免疫组化及Western-blot检测显示20μmol/L的9-cis-RA作用72h后,RXRγ、RARβ蛋白表达增加。结论:9-cis-RA可通过上调RXRγ、RARβ蛋白表达诱导细胞凋亡从而抑制人胃癌SGC7901细胞生长。Objective：To investigate the inhibitory effect of RXRγ and RARβ on the growth of human gastric carcinoma cell line SGC7901 treated by RXR agonist（9-cis-RA）. Methods：The human gastric carcinoma cell line SGC7901 was treated with 9-cis-RA, and then the morphological changes were observed by H-E staining. The cell growth was detected by MTT as- say. The apoptosis and the cell cycle progression were analyzed by flow cytometry. The expressions of RXRγ and RARβ were detected by immunocytochemistry staining and western-blot assay. Results： HE stain showed that the SGC7901 cells were sparser with the increasing concentration of 9-cis-RA. The growth of SGC7901 cell was inhibited by 9-cis-RA at the concen- tration of 20 μmol/L in time and dose depended manner. The apoptotic rate of the tumor cells increased after 72 hours at the concentration of 20 μmol/L 9-cis-RA and the tumor cells were arrested in G0/G1 phase. Immunocytochemistry and Western- blot assay showed that the expressions of RXRγ and RARβ increased after 72 hours, compared with those of negative control group. Conclusion： RXR agonist 9-cis-RA can inhibit the growth of SGC7901 cells via inducing cell apoptosis through up- grading the expressions of RXRγ and RARβ.

关 键 词：维甲类X受体γ 受体 维甲酸 胃肿瘤 癌 肿瘤细胞 培养的 SGC7901细胞株 

分 类 号：R735.2[医药卫生—肿瘤] R977[医药卫生—临床医学]